Cerebral Palsy Clinical Trial
Official title:
Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy
Verified date | January 2022 |
Source | University of Arizona |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cerebral palsy (CP) is a non-progressive disorder caused by an insult or injury to the brain when the brain is most rapidly developing and which results in some motor dysfunction. Causes for the injury to the brain are numerous and can occur prior to birth, during the birth process, or within the first few months following birth. The motor dysfunction can involve any or all four extremities but most often affects the legs, causing abnormal ambulation. The level of severity depends on the extent of the injury to the brain and can be mild to severe. In severe instances, the child is dependent on others for all his/her care. There is no known cure for CP, but physical and occupational therapies are administered in an attempt to improve function. The frequency of these therapies varies from once a week (the standard of care in the Western Hemisphere) to five times a week (the standard of care in Asia and some Eastern European countries). The current understanding of brain plasticity offers a theoretical explanation to justify the more intense approach. Active repetitive motor skill-directed rehabilitation utilizes the plasticity of the brain and can restore some function. Intense active physiotherapy can stimulate non-injured but 'dormant' neurons and prevent their 'natural' degeneration in order for them to substitute for the function of injured neurons. It is the very young brain that is most likely to respond to this therapy. The aim of this proposal is to evaluate the effect of administering both physical and occupational therapy five times each week for 12 weeks and compare it with the standard of care (SOC) approach of one time each week in children between the ages of 12 months and 36 months. This is the first randomized crossover trial to both enroll this young a population of children with cerebral palsy as well as to evaluate this approach from both the therapists and the parents perspectives. The number of children that this study will enroll is larger than in most CP studies. The children will be evaluated clinically with two validated instruments, one of which was designed specifically for children with CP and is administered and scored by certified therapists and the other which was designed for children with developmental disabilities and is scored by the child's care provider. A sub-set of children will have a special type of MRI to evaluate any changes in the neurological structure of the brain. The Department of Pediatrics at the University of Arizona recently completed a collaborative study with the Neurologic Department at the Beijing Children's Hospital where the intense approach of five therapies per week is the SOC. The positive results prompted another investigation to determine if such an approach would be feasible in the United States. A compliance rate of 81% confirmed feasibility and the perception that parents who have a child diagnosed with CP will do whatever they can to improve their child's motor function.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 31, 2021 |
Est. primary completion date | July 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Months to 36 Months |
Eligibility | Inclusion Criteria: 1. Age: 12 to 36 months of age (The diagnosis of CP is often uncertain under the age of 12 months. The cutoff at 36 months is to have a population of young children when the brain is most "plastic" and most susceptible to reorganization). 2. Diagnosis: Diagnosis of spastic CP confirmed by a pediatric neurologist or pediatric rehabilitation specialist. 3. Etiology: The insult to the central nervous system that caused the motor dysfunction must have occurred during gestation or within one year after birth independent of gestational age. 4. Disease severity level: Gross Motor Function Classification System (GMFCS) levels I, II and III. Exclusion Criteria: 1. Diagnosis: Diagnosis of CP secondary to neuronal migration. 2. Co-morbidities: Medical conditions that may prevent the administration of rehabilitation therapies at the intensity required by the study, or that may compromise the study ability to maintain blindness, or that have a co-morbidity not typically associated with CP (i.e. cancer, cystic fibrosis). 3. Co-interventions: Anticipated pharmacological intervention or procedure or participation in other studies that may interfere with this study. |
Country | Name | City | State |
---|---|---|---|
United States | Nemours Children's Hospital | Orlando | Florida |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | United Cerebral Palsy-Central Arizona | Phoenix | Arizona |
United States | Tucson Medical Center | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
University of Arizona | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Nemours Children's Hospital, Phoenix Children's Hospital, Tucson Medical Center, United Cerebral Palsy-Central Arizona |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Magnetic Resonance Imaging (MRI)/Diffusion Tensor MRI (DTI) | As part of an exploratory aim, imaging studies will be done at the Barrow Neurological Institute at Phoenix Children's Hospital on a small subset of enrolled children with hemiplegia. Ten children from each of the two randomized groups stratified for age and severity will be imaged before therapy and at 36 weeks after the beginning of therapy. The purpose of this subset is to evaluate white matter integrity and connectivity throughout the entire brain. Differences at 36 weeks will be indicative of alterations in white matter and connectivity scores due to therapy. | Change from Baseline at 36 weeks | |
Primary | Change in Gross Motor Function Measure-66 (GMFM-66) | The primary aim is to assess function. The evaluation instruments we chose are standard in CP research and include an assessment by a certified therapist of Gross Motor Function Measure-66 (GMFM-66) and a parental assessment of the child's functional abilities in the home environment (PEDI-FS). For the primary and secondary outcomes, these endpoints will be assessed at baseline and at 12 weeks as well as every 12 weeks for the next 36 weeks. The evaluation at 48 weeks after the completion of the intense schedule allows an estimation of the persistence of change.
The GMFM-66 is a criterion referenced validated instrument that has been shown to detect change in gross motor function (performance) of children with CP as a result of various interventions. The 66 test items have been grouped into five dimensions: (1) lying and rolling; (2) crawling and kneeling; (3) sitting, standing and walking; (4) running, and (5) jumping. |
Change from Baseline at 12 weeks, 24 weeks, 36 weeks, and 48 weeks | |
Secondary | Change in Pediatric Evaluation of Disability Inventory-Functional Skills (PEDI-FS) | The primary aim is to assess function. The evaluation instruments we chose are standard in CP research and include an assessment by a certified therapist of Gross Motor Function Measure-66 (GMFM-66) and a parental assessment of the child's functional abilities in the home environment (PEDI-FS). For the primary and secondary outcomes, these endpoints will be assessed at baseline and at 12 weeks as well as every 12 weeks for the next 36 weeks. The evaluation at 48 weeks after the completion of the intense schedule allows an estimation of the persistence of change.
The PEDI-FS is an instrument developed specifically for children from 6 months through 7 years of age who have some type of a disability. It is a child's primary care provider's assessment of what skills the child is able to perform. The skills are grouped into three domains: (1) self-care, (2) mobility, and (3) social function. |
Change from Baseline at 12 weeks, 24 weeks, 36 weeks, and 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05317234 -
Genetic Predisposition in Cerebral Palsy
|
N/A | |
Recruiting |
NCT05576948 -
Natural History of Cerebral Palsy Prospective Study
|
||
Completed |
NCT04119063 -
Evaluating Wearable Robotic Assistance on Gait
|
Early Phase 1 | |
Completed |
NCT03264339 -
The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy
|
N/A | |
Completed |
NCT05551364 -
Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT03902886 -
Independent Walking Onset of Children With Cerebral Palsy
|
||
Recruiting |
NCT05571033 -
Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy
|
N/A | |
Not yet recruiting |
NCT04081675 -
Compliance in Children With Cerebral Palsy Supplied With AFOs
|
||
Completed |
NCT04012125 -
The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy
|
N/A | |
Enrolling by invitation |
NCT05619211 -
Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities
|
Phase 1 | |
Completed |
NCT04489498 -
Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
|
||
Completed |
NCT03677193 -
Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy
|
N/A | |
Recruiting |
NCT06450158 -
Robot-assisted Training in Children With CP
|
N/A | |
Completed |
NCT04093180 -
Intensive Neurorehabilitation for Cerebral Palsy
|
N/A | |
Completed |
NCT02909127 -
The Pediatric Eating Assessment Tool
|
||
Not yet recruiting |
NCT06377982 -
Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy
|
Phase 1 | |
Not yet recruiting |
NCT06007885 -
Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention.
|
N/A | |
Not yet recruiting |
NCT03183427 -
Corpus Callosum Size in Patients With Pineal Cyst
|
N/A | |
Active, not recruiting |
NCT03078621 -
Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy
|
Phase 1/Phase 2 | |
Completed |
NCT02897024 -
A Comparison: High Intense Periodic vs. Every Week Therapy in Children With Cerebral Palsy (ACHIEVE)
|
N/A |